5 Key Takeaways

• 1

  Bausch + Lomb is advancing a dual-action dry eye drop combining lifitegrast and PFHO, moving to Phase 3 after Phase 2 results.

• 2

  The dual-action therapy showed a significant reduction in corneal fluorescein staining at Day 15 compared to lifitegrast alone.

• 3

  Bausch + Lomb's formulation uses over 50% less lifitegrast and is dosed at half the frequency of existing therapies.

• 4

  BL1332, a TRPV1 antagonist, met its primary endpoint in a Phase 1b study, showing significant pain reduction in treated eyes.

• 5

  BL1332 is now in Phase 2 trials for pain following photorefractive keratectomy, with results expected soon.